Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Mortazavi

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
European Journal of Drug Metabolism and Pharmacokinetics|October 7, 2021
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized DosingSophia Liva, Min Chen, Amir Mortazavi, et al.
Investigational New Drugs|February 1, 2006
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)Tanios S Bekaii-Saab, Amir Mortazavi, Lee G Hicks, et al.
Cancer Medicine|November 8, 2019
Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancerMing Yin, Jing Zhao, Paul Monk, et al.
American Journal of Clinical Oncology|February 3, 2005
Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study?Amir Mortazavi, Aasma Shaukat, Edress Othman, et al.
Cancer Drug Resistance (Alhambra, Calif.)|March 7, 2025
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesAdam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 21, 2017
Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?Huyen T Nguyen, Amir Mortazavi, Kamal S Pohar, et al.
Cells|January 11, 2024
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell CarcinomaLingbin Meng, Katharine A Collier, Peng Wang, et al.
European Radiology|August 25, 2016
Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I studyHuyen T Nguyen, Zarine K Shah, Amir Mortazavi, et al.
Analytical and Bioanalytical Chemistry|August 6, 2011
Potential analytical applications of lysenin channels for detection of multivalent ionsDaniel Fologea, Redwan Al Faori, Eric Krueger, et al.
Cancers|January 23, 2024
A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and VaccinesDixita M Patel, Ruba Mateen, Noor Qaddour, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
European Journal of Drug Metabolism and Pharmacokinetics|October 7, 2021
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized DosingSophia Liva, Min Chen, Amir Mortazavi, et al.
Investigational New Drugs|February 1, 2006
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)Tanios S Bekaii-Saab, Amir Mortazavi, Lee G Hicks, et al.
Cancer Medicine|November 8, 2019
Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancerMing Yin, Jing Zhao, Paul Monk, et al.
American Journal of Clinical Oncology|February 3, 2005
Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study?Amir Mortazavi, Aasma Shaukat, Edress Othman, et al.
Cancer Drug Resistance (Alhambra, Calif.)|March 7, 2025
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesAdam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 21, 2017
Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?Huyen T Nguyen, Amir Mortazavi, Kamal S Pohar, et al.
Cells|January 11, 2024
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell CarcinomaLingbin Meng, Katharine A Collier, Peng Wang, et al.
European Radiology|August 25, 2016
Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I studyHuyen T Nguyen, Zarine K Shah, Amir Mortazavi, et al.
Analytical and Bioanalytical Chemistry|August 6, 2011
Potential analytical applications of lysenin channels for detection of multivalent ionsDaniel Fologea, Redwan Al Faori, Eric Krueger, et al.
Cancers|January 23, 2024
A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and VaccinesDixita M Patel, Ruba Mateen, Noor Qaddour, et al.
Pageof 9